CERAGEM Co. said on the 13th that it posted 549.8 billion won in revenue and 25.8 billion won in operating profit in 2025, sharply improving profitability. Revenue rose 0.7% from a year earlier, while operating profit jumped 1,091%. Net profit turned positive at 1.9 billion won.
CERAGEM Co. said the investments it has continued and its strategy to upgrade its business structure led to improved results. The company has pursued portfolio diversification by expanding products and services around its "7-care solution." As a result, it kept revenue stable while boosting profitability.
CERAGEM Co.'s "7-care solution" is an integrated healthcare strategy based on seven health elements, including the spine, exercise and rest. CERAGEM Co. strengthened the competitiveness of its existing flagship products, such as the spine care medical device certified by the Ministery of Food and Drug Safety, "Master V Collection," and the massage chair "Pause M Collection," while expanding new product lines, including the blood circulation improvement medical device "Celtron Circulation Chair," the alkaline ion water generator "CERAGEM Balance," and the beauty device "Medispa," upgrading its revenue structure.
A strategy to enhance customer experience centered on offline experiential stores also proved effective. While flagship product lines maintained stable revenue, new products and services drove additional growth.
Research and development (R&D) investment is also translating into results. CERAGEM Co. invested 18.9 billion won in 2023, 19.1 billion won in 2024 and 24.2 billion won in 2025, continuing technology upgrades and new product development. The company said these preemptive investments are leading to improved profitability and creating a virtuous cycle.
CERAGEM Co. is strengthening its business in emerging markets such as Southeast Asia, India and Latin America. Its strategy is to secure medium- to long-term global competitiveness by restructuring its portfolio around markets with high growth potential.
A CERAGEM Co. official said, "The 2025 results are not just a recovery but a turning point where the outcomes of past investments have begun to be reflected in earnest," adding, "We will continue a stable growth trajectory by strengthening competitiveness around the '7-care solution' and our AI wellness home vision."